Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · REGISTER · 2002-09-26 · Food and Drug Administration, HHS · Rules and Regulations

Rules and Regulations. Notice

287 words·~1 min read·/register/2002/09/26/02-24561

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4163-18-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee; Amendment of Notice AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration
(FDA)is announcing an amendment to the notice of meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. This meeting was announced in the **Federal Register** of August 1, 2002 (67 FR 49945). The amendment is being made to reflect a change in the *Agenda* portion of the document. The meeting was originally scheduled for September 25, 26, and 27, 2002. However, due to administrative complications, the discussions on September 26 and 27, 2002, will be postponed until a later date. There are no other changes. FOR FURTHER INFORMATION CONTACT: Kathleen Reedy, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, FAX 301-827-6776, or e-mail: *reedyk@cder.fda.gov* , or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12536, for up-to-date information on this meeting. SUPPLEMENTARY INFORMATION: In the **Federal Register** of August 1, 2002, FDA announced that a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee would be held on September 25, 26, and 27, 2002. On page 49945, in the first column, the *Agenda* portion of the meeting is amended to read as follows: *Agenda* : On September 25, 2002, the committee will discuss appropriate designs for clinical trials of new osteoporosis treatments. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees. Dated: September 23, 2002. Linda Arey Skladany, Senior Associate Commissioner for External Relations. [FR Doc. 02-24561 Filed 9-23-02; 5:02 pm]
Connections1 off-index
1 reference not yet in our index
  • 21 CFR 14
Citation graph
cites case law
Rules and Regulations
Notice
Cite21 CFR 14
Cites 1Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.